Agenus Stock News

Agenus Inc. (AGEN) with the stream of -3.31% also noticed, India Delcath Systems, Inc. (DCTH) encountered a rapid change of -13.36% in the last hour of Fridays trading session. Agenus The post Miraculous Stock: Agenus Inc. (NASDAQ:AGEN), Delcath Systems, Inc. (NASDAQ:DCTH) appeared first on Stocks Equity .

Price T Rowe Associates Inc. MD grew its position in shares of Agenus Inc. (NASDAQ:AGEN) by 16.7% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 44,684 shares of the biotechnology companys stock after acquiring an additional 6,408 shares during the []

Agenus (NASDAQ:AGEN) was upgraded by TheStreet from a d- rating to a c+ rating in a research report issued to clients and investors on Wednesday, TheStreetRatingsTable reports. Several other equities research analysts have also weighed in on AGEN. Zacks Investment Research lowered Agenus from a buy rating to a hold rating in a research note []

Metropolitan Life Insurance Co NY boosted its position in Agenus Inc. (NASDAQ:AGEN) by 217,508.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 54,402 shares of the biotechnology companys stock after buying an additional 54,377 shares during the quarter. Metropolitan Life Insurance Co NYs []

Renaissance Technologies LLC lowered its position in Agenus Inc. (NASDAQ:AGEN) by 88.1% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 70,015 shares of the biotechnology companys stock after selling 520,200 shares during the period. Renaissance Technologies LLCs holdings in Agenus were []

In the last trading session, 3.4 million shares of the Agenus Inc. (NASDAQ:AGEN) were traded, and its beta was 1.09. Most recently the companys share price was $3.49, and it changed around -$0.09 or -2.51% from the last close, which brings the market valuation of the company to $919.51M. AGEN currently trades at a discount Agenus Inc. (NASDAQ: AGEN) Is Something To Consider Today. Read More »

Here's three penny stocks to watch right now The post 3 Penny Stocks to Add to Your Watch List Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Here's three penny stocks to watch right now The post 3 Penny Stocks to Add to Your Watch List Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Lynch & Associates IN grew its stake in Agenus Inc. (NASDAQ:AGEN) by 25.6% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 26,493 shares of the biotechnology companys stock after purchasing an additional 5,393 shares during the period. Lynch & Associates INs holdings []

California State Teachers Retirement System increased its holdings in shares of Agenus Inc. (NASDAQ:AGEN) by 14.6% in the 2nd quarter, Holdings Channel.com reports. The firm owned 271,826 shares of the biotechnology companys stock after acquiring an additional 34,694 shares during the quarter. California State Teachers Retirement Systems holdings in Agenus were worth $1,492,000 as of []

Agenus Inc. (NASDAQ:AGEN) price on Thursday, November 18, rose 1.42% above its previous days close as an upside momentum from buyers pushed the stocks value to $3.58. A look at the stocks price movement, the close in the last trading session was $3.53, moving within a range at $3.41 and $3.68. The beta value (5-Year Honey At Agenus Inc. (AGEN) Is Worth Your Money Read More »

Agenus Inc. (NASDAQ:AGEN) Analysts at William Blair decreased their FY2021 EPS estimates for Agenus in a research note issued to investors on Monday, November 15th. William Blair analyst M. Phipps now expects that the biotechnology company will post earnings of ($0.11) per share for the year, down from their previous forecast of ($0.10). William []

Adaptimmune Therapeutics and Agenus are having a tough go of it in the final quarter of 2021.

Equities research analysts forecast that Agenus Inc. (NASDAQ:AGEN) will announce ($0.12) earnings per share for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Agenus earnings, with the highest EPS estimate coming in at ($0.04) and the lowest estimate coming in at ($0.16). Agenus posted earnings of ($0.20) per share in the []

In a Phase I study across nine tumor types, Agenus Inc's (NASDAQ: AGEN) CTLA-4 drug AGN1181 posted one complete response and three partial responses (PRs) as a monotherapy, according to data prese